Safety of Continuous Nebulized Albuterol for Bronchospasm in Infants and Children
1 From the Division of Pulmonary/Critical Care Medicine, Department of Pediatrics, School of Pharmacy, University of New Mexico, School of Medicine, Albuquerque
Objective. To determine the incidence of cardiotoxicity in infants and children who receive continuous nebulized albuterol (CNA) for bronchospasm.
Design. Prospective, case series.
Setting. A university pediatric intensive care and pediatric subacute units.
Patients. Nineteen infants and children who received CNA for at least 24 hours.
Interventions. None.
Measurements. Creatinine phosphokinase (CK) was measured at the time of admission and then at 12,24,48, and 72 hours while the patient received CNA. Isoenzyme CK-MB fractions were measured if CK concentration was 
250 IU/L. One electrocardiogram was obtained for each patient during CNA treatment. All patients had continuous cardiac monitoring during continuous nebulization therapy.
Main results. Creatinine phosphokinase levels remained within normal limits for 16 patients during CNA treatment. Three patients had elevated CK and in two CK-MB fractions were elevated at one measurement. None of the electrocardiograms showed evidence of ischemia and no arrhythmias were noted during CNA therapy, even in the patients with elevated CK-MB fractions.
Conclusions. Continuous albuterol therapy appears to be safe in our patient population as there was no significant evidence of cardiotoxicity. The significance of the transient elevation of CK-MB without other evidence of cardiotoxicity remains to be determined.
Key Words: talbuterol • continuous nebulization • bronchospasm • cardiotoxicity • myocardial ischemia • creatinine phosphokinase • arrhythmia
Submitted on February 26, 1993
Accepted on May 13, 1993
This article has been cited by other articles:
 |
|
 |
|
  H W. Kelly, K. A Keim, and B. C McWilliams Comparison of Two Methods of Delivering Continuously Nebulized Albuterol Ann. Pharmacother., January 1, 2003; 37(1): 23 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Rodrigo and C. Rodrigo Continuous vs Intermittent {beta}-Agonists in the Treatment of Acute Adult Asthma* : A Systematic Review With Meta-analysis Chest, July 1, 2002; 122(1): 160 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Werner Status Asthmaticus in Children : A Review Chest, June 1, 2001; 119(6): 1913 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Ream, L. L. Loftis, G. M. Albers, B. A. Becker, R. E. Lynch, and R. B. Mink Efficacy of IV Theophylline in Children With Severe Status Asthmaticus Chest, May 1, 2001; 119(5): 1480 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. W. Kelly The Management of Acute Severe Asthma Journal of Pharmacy Practice, April 1, 2001; 14(2): 91 - 107. [Abstract] [PDF]
|
|
|
|
 |
|
 D. J. Gutglass, L. Hampers, G. Roosevelt, D. Teoh, S. R. Nimmagadda, and S. E. Krug Undiluted Albuterol Aerosols in the Pediatric Emergency Department Pediatrics, May 1, 2000; 105(5): 67e - 67. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Everett Alternatives to Standard Status Asthmaticus Therapy Journal of Pharmacy Practice, June 1, 1997; 10(3): 186 - 199. [Abstract] [PDF]
|
|
|
|
 |
|
 CONTINUOUS NEBULIZED ALBUTEROL IS SAFE IN CHILDREN Journal Watch (General), November 23, 1993; 1993(1123): 3 - 3. [Full Text]
|
|
